Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27829997 | 1.00 | CA2 (0.47) | CA2ZDHHC7CA1GRIK1GRIK2 | |
| SCHEMBL28648541 | 1.00 | CA2 (0.47) | CA2ZDHHC7CA1GRIK1GRIK2 | |
| SCHEMBL25422481 | 1.00 | CA2 (0.47) | CA2ZDHHC7CA1GRIK1GRIK2 | |
| SCHEMBL5981783 | 0.98 | CA2 (0.44) | CA2ZDHHC7CA1GRIK1GRIK2 | |
| Hydrochloric Acid SCHEMBL29134420 | 0.96 | CA2 (0.43) | CA2ZDHHC7CA1GRIK1GRIK2 | |
| SCHEMBL18597124 | 0.96 | CA2 (0.50) | CA2ZDHHC7CA1GRIK1GRIK2 | |
| SCHEMBL7367485 | 0.96 | CA2 (0.50) | CA2ZDHHC7CA1GRIK1GRIK2 | |
| SCHEMBL22880855 | 0.96 | CA2 (0.50) | CA2ZDHHC7CA1GRIK1GRIK2 | |
| SCHEMBL28380817 | 0.96 | CA2 (0.50) | CA2ZDHHC7CA1GRIK1GRIK2 | |
| SCHEMBL28381502 | 0.96 | CA2 (0.50) | CA2ZDHHC7CA1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117683051-A | Tetraheterocyclic compound, preparation method thereof, intermediate thereof and application thereof | 上海艾力斯医药科技股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117616030-A | Orexin receptor agonists and uses thereof | 爵士制药爱尔兰有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117157285-A | Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors | 阿尔麦克探索有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-116829151-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-114835687-B | AhR inhibitors | 北京华森英诺生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116670143-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-111793077-B | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 东莞市东阳光新药研发有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-116239541-B | N-phenyl-2-oxo quinazoline compound and application thereof | 英矽智能科技(上海)有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116239541-A | N-phenyl-2-oxo quinazoline compound and application thereof | 英矽智能科技(上海)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-116209438-A | Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors | 锐新医药公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-109562113-A | Spirocyclo-rongeur for target protein degradation | C4医药公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-108289886-A | Ion channel inhibiting compound, pharmaceutical preparation and purposes | 安华赛公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-104245693-A | Pyrimidine derivative and pharmaceutically acceptable salt thereof, preparation method and medical application thereof | SHANGHAI HENGRUI PHARM CO LTD | 2014-12-24 | — | — | CN | disclosed |
| CN-102382129-B | Spirocycles-substituted phosphodiesterase inhibitor | KBP BIOSCIENCES CO LTD | 2014-02-26 | — | — | CN | disclosed |
| CN-102382129-A | Spirocycles-substituted phosphodiesterase inhibitor | KBP BIOSCIENCES CO LTD | 2012-03-21 | — | — | CN | disclosed |
| CN-101472912-A | Pyridine and pyrazine derivatives as MNK kinase inhibitors | BIOVITRUM AB PUBL (SE) | 2009-07-01 | — | — | CN | disclosed |
| CN-1639152-A | Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors | LILLY CO ELI (US) | 2005-07-13 | — | — | CN | disclosed |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1272484-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001077100-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | TACR1, VIPR1, VIPR2 | CA2 1332/4885ZDHHC7 2793/4885CA1 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.